Frontotemporal dementia therapy programs reach late-stage trials
Progranulin-replacement therapy in GRN-mutation FTD, ASO programs in C9orf72 FTD-ALS, and tau-targeted programs are emerging in a previously bare category.
Frontotemporal dementia (FTD) has been a no-specific-therapy category with supportive care and off-label SSRI for behavioural symptoms. Late-stage programs include progranulin-replacement therapy for GRN-mutation FTD, ASO programs for C9orf72-mutation FTD-ALS spectrum disease, and tau-targeted programs for tau-pathology subtypes. The genetic-testing infrastructure for FTD (a meaningful fraction of cases are inherited) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.